Free Trial

Fresenius SE & Co. (OTCMKTS:FSNUY) Sees Unusually-High Trading Volume - Should You Buy?

Fresenius SE & Co. logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Shares experienced unusually high trading volume of 281,087 shares (a 294% increase from 71,377) while the stock dipped to $12.51, down about 1.6% from the prior close.
  • Brokerages maintain a positive view with a consensus Buy rating—three analysts rate the stock Buy, and both Citigroup and Morgan Stanley recently reiterated bullish ratings.
  • Key fundamentals: market cap $28.2B and a PE of 19.87; last quarter EPS was $0.28 on $6.94B revenue, analysts forecast roughly $0.79 EPS for the year, and the stock sits below its 50- and 200-day moving averages.
  • Five stocks to consider instead of Fresenius SE & Co..

Shares of Fresenius SE & Co. (OTCMKTS:FSNUY - Get Free Report) saw strong trading volume on Thursday . 281,087 shares traded hands during mid-day trading, an increase of 294% from the previous session's volume of 71,377 shares.The stock last traded at $12.51 and had previously closed at $12.7250.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on FSNUY. Citigroup restated a "buy" rating on shares of Fresenius SE & Co. in a research note on Tuesday, February 3rd. Morgan Stanley reiterated an "overweight" rating on shares of Fresenius SE & Co. in a report on Monday, December 15th. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy".

Check Out Our Latest Stock Report on Fresenius SE & Co.

Fresenius SE & Co. Trading Down 1.6%

The firm has a 50 day moving average of $14.13 and a 200 day moving average of $14.36. The firm has a market cap of $28.20 billion, a PE ratio of 19.87 and a beta of 0.75. The company has a quick ratio of 0.99, a current ratio of 1.26 and a debt-to-equity ratio of 0.49.

Fresenius SE & Co. (OTCMKTS:FSNUY - Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The company reported $0.28 earnings per share for the quarter. The company had revenue of $6.94 billion during the quarter. Fresenius SE & Co. had a return on equity of 10.38% and a net margin of 5.71%. Equities analysts anticipate that Fresenius SE & Co. will post 0.79 earnings per share for the current year.

Fresenius SE & Co. Company Profile

(Get Free Report)

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world's leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Fresenius SE & Co. Right Now?

Before you consider Fresenius SE & Co., you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius SE & Co. wasn't on the list.

While Fresenius SE & Co. currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPOs On Wall Street’s 2026 Watchlist Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines